Possible neuroleptic malignant syndrome related to concomitant treatment with paroxetine and alprazolam

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 30, Issue 6, 2006, Pages 1176-1178

  Tanii, Hisashi ^a,b   Ichihashi, Kayo ^b   Inoue, Ken ^a   Fujita, Kohei ^b   Okazaki, Yuji ^a  

^a MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Hinaga General Hospital for Mental Care   (Japan)

Author keywords

Alprazolam; Depression; Neuroleptic malignant syndrome; Paroxetine

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPRAZOLAM; ASPARTATE AMINOTRANSFERASE; BROMOCRIPTINE; CREATINE KINASE; DIAZEPAM; NITROGEN; PAROXETINE; UREA;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; AGED; AGING; AGITATION; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALGORITHM; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD PRESSURE MEASUREMENT; CASE REPORT; CREATINE KINASE BLOOD LEVEL; DEHYDRATION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE SEVERITY; DISORIENTATION; DRUG FEVER; ENVIRONMENTAL FACTOR; EXHAUSTION; EXTRAPYRAMIDAL SYMPTOM; HOSPITAL ADMISSION; HUMAN; HYPOTENSION; INSOMNIA; LABORATORY TEST; LEUKOCYTE COUNT; MAJOR DEPRESSION; MALE; MALNUTRITION; MENTAL HOSPITAL; MUSCLE RIGIDITY; NEUROLEPTIC MALIGNANT SYNDROME; PSYCHOMOTOR RETARDATION; RISK FACTOR; SYMPTOM; SYMPTOMATOLOGY; TEMPERATURE; TREATMENT OUTCOME; TREMOR; UREA NITROGEN BLOOD LEVEL;

AGED; ALPRAZOLAM; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; DEPRESSIVE DISORDER; DRUG THERAPY, COMBINATION; HUMANS; HYPNOTICS AND SEDATIVES; MALE; NEUROLEPTIC MALIGNANT SYNDROME; PAROXETINE; PSYCHIATRIC STATUS RATING SCALES;

EID: 33745286824     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2006.04.006     Document Type: Article

References (25)

1. American Psychiatric Association. DSM-IV, Diagnostic and Statistical Manual of Mental Disorders. 4th ed. (1994), American Psychiatric Association, Washington 741-742
2. Burch Jr. E.A., and Downs J. Development of neuroleptic malignant syndrome during simultaneous amoxapine treatment and alprazolam discontinuation. J Clin Psychopharmacol 7 (1987) 55-56
3. Carroll B.T., and Taylor R.E. The nondichotomy between lethal catatonia and neuroleptic malignant syndrome. J Clin Psychopharmacol 17 (1997) 235-236
4. Cassidy E.M., O'Brien M., Osman M.F., Finucane J., and O'Keane V. Lethal catatonia responding to high-dose olanzapine therapy. J Psychopharmacol 15 (2001) 302-304
5. Castillo E., Rubin R.T., and Holsboer-Trachsler E. Clinical differentiation between lethal catatonia and neuroleptic syndrome. Am J Psychiatry 146 (1989) 324-328
6. Corradetti R., Ruggiero M., Chiarugi V.P., and Pepeu G. GABA-receptor stimulation enhances norepinephrine-induced polyphosphoinositide metabolism in rat hippocampal slices. Brain Res 411 (1987) 196-199
7. Ebari M., Pfeiffer R.F., and Murrin L.C. Pathogenesis and treatment of neuroleptic malignant syndrome. Gen Pharmacol 21 (1990) 367-386
8. Giardino L., Zanni M., Pozza M., Bettelli C., and Covelli V. Dopamine receptors in the striatum of rats exposed to repeated restraint stress and alprazolam treatment. Eur J Pharmacol 344 (1998) 143-147
9. Gupta S., and Racaniello A.A. Neuroleptic malignant syndrome associated with amoxapine and lithium in an older adult. Ann Clin Psychiatry 12 (2000) 107-109
10. Hashimoto F., Sherman C.B., and Jeffery W.H. Neuroleptic malignant syndrome and dopaminergic blockade. Arch Intern Med 144 (1984) 629-630
11. Henderson V.W., and Wooten G.F. Neuroleptic malignant syndrome: a pathogenetic role for dopamine receptor blockade?. Neurology 31 (1981) 132-137
12. Isbister G.K., O'Regan L., Sibbritt D., and Whyte I.M. Alprazolam is relatively more toxic than other benzodiazepines in overdose. Br J Clin Pharmacol 58 (2004) 88-95
13. Kontaxakis V.P., Havaki-Kontaxaki B.J., Christodoulou N.G., Paplos K.G., and Christodoulou G.N. Olanzapine-associated neuroleptic malignant syndrome: is there an overlap with the serotonin syndrome?. Ann Gen Hosp Psychiatry 2 (2003) 10
14. Kontaxakis V.P., Havaki-Kontaxaki B.J., Pappa D.A., Katritsis D.E., and Christodoulou G.N. Neuroleptic malignant syndrome after addition of paroxetine to olanzapine. J Clin Psychopharmacol 23 (2003) 671-672
15. Kumar V. A case of neuroleptic malignant syndrome treated with diazepam. Can J Psychiatry 32 (1987) 815-816
16. Langlow J.R., and Alarcon R.D. Trimipramine-induced neuroleptic malignant syndrome after transient psychogenic polydipsia in one patient. J Clin Psychiatry 50 (1989) 144-145
17. Lew T.Y., and Tollefson G. Chlorpromazine-induced neuroleptic malignant syndrome and its response to diazepam. Biol Psychiatry 18 (1983) 1441-1446
18. Naranjo C.A., Busto U., Sellers E.M., Sandor P., Ruiz I., Roberts E.A., et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30 (1981) 239-245
19. Radomski J.W., Dursun S.M., Reveley M.A., and Kutcher S.P. An exploratory approach to the serotonin syndrome: an update of clinical phenomenology and revised diagnostic criteria. Med Hypotheses 55 (2000) 218-224
20. Rusyniak D.E., and Sprague J.E. Toxin-induced hyperthermic syndromes. Med Clin North Am 89 (2005) 1277-1279
21. Santagostino G., Cucchi M.L., Frattini P., Zerbi F., Di Paolo E., Preda S., et al. The influence of alprazolam on the monoaminergic neurotransmitter systems in dysthymic patients. Relationship to clinical response. Pharmacopsychiatry 31 (1998) 131-136
22. Taylor N.E., and Schwartz H.I. Neuroleptic malignant syndrome following amoxapine overdose. J Nerv Ment Dis 176 (1988) 249-251
23. Tsai H.C., Kuo P.H., and Yang P.C. Fever, consciousness disturbance, and muscle rigidity in a 68-year-old man with depressive disorder. Chest 124 (2003) 1598-1601
24. Van Den Eede F., Van Hecke J., Van Dalfsen A., Van den Bossche B., Cosyns P., and Sabbe B.G. The use of atypical antipsychotics in the treatment of catatonia. Eur Psychiatry 20 (2005) 422-429
25. Washington C., Haines K.A., and Tam C.W. Amoxapine-induced neuroleptic malignant syndrome. DICP 23 (1989) 713